Aquestive Therapeutics (AQST) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aquestive Therapeutics (AQST) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, losing 23.2% versus a loss of 35.5%. Over five years, AQST leads with a +23.0% price change compared with -78.1% for PHAT. Aquestive Therapeutics is the larger company by market cap ($597.4 million vs $576.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | PHAT |
|---|---|---|
| Share price | $4.76 | $7.13 |
| Market cap | $597.44M | $576.82M |
| 1-day change | +3.03% | +4.70% |
| YTD return | -26.32% | -57.02% |
| 1-year return | -23.23% | -35.48% |
| 5-year return | +23.00% | -78.07% |
| Forward P/E | — | 6.62 |
| EPS (TTM) | $-0.66 | $-1.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.55 | $18.31 |
| 52-week low | $2.93 | $6.52 |
| Distance from 52-week high | -36.95% | -61.06% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +96.01% | +186.82% |
| Average volume | 2.68M | 1.38M |
| Shares outstanding | 125.51M | 80.90M |
| Employees | 147 | 371 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AQST has outperformed PHAT by 12.2 percentage points over the past year.
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Healthcare · Drug Manufacturers - Specialty & Generic · 147 employees
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Healthcare · Biotechnology · 371 employees
AQST vs PHAT FAQ
Which is bigger, Aquestive Therapeutics or Phathom Pharmaceuticals?
Aquestive Therapeutics (AQST) is larger, with a market capitalization of $597.44M compared with $576.82M for Phathom Pharmaceuticals (PHAT).
Which stock has performed better over the past year, AQST or PHAT?
AQST returned -23.23% over the past 12 months, compared with -35.48% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Phathom Pharmaceuticals in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Aquestive Therapeutics and Biotechnology for Phathom Pharmaceuticals.